CIK 0001426800
ASMB ASSEMBLY BIOSCIENCES, INC.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at ASSEMBLY BIOSCIENCES, INC., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 38Weak | buy 2 | Houghton Michael director | $50k | 3,202 | - | - | |
| 50Moderate | buy 2 | GILEAD SCIENCES, INC. owner | $20M | 940,499 | +74% | - | |
| 22Weak | buy | Schornstein Alexander owner | $372k | 25,000 | +4% | - | |
| 15Weak | sell | White Nicole S Chief Manufacturing Officer | $652 | 40 | -0% | - |
Transactions
The last 6 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Houghton Michael director | POpen-market purchase Common Stockindirect: By IRA | +3,202 | $15.61 | $50k | 3,202 | Dec 31, 2024 |
| Dec 19, 2024 | GILEAD SCIENCES, INC. owner | POpen-market purchase Common Stock | +940,499 | $21.37 | $20M | 2,209,471 | Dec 23, 2024 |
| Nov 22, 2024 | Schornstein Alexander owner | POpen-market purchase Common Stock | +17,024 | $14.87 | $253k | 720,137 | Nov 26, 2024 |
| Nov 25, 2024 | Schornstein Alexander owner | POpen-market purchase Common Stock | +2,976 | $15.00 | $45k | 723,113 | Nov 26, 2024 |
| Nov 25, 2024 | Schornstein Alexander owner | POpen-market purchase Common Stock | +5,000 | $14.85 | $74k | 728,113 | Nov 26, 2024 |
| Nov 18, 2024 | White Nicole S Chief Manufacturing Officer | SOpen-market sale Common Stock | -40 | $16.29 | $652 | 11,871 | Nov 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- GILEAD SCIENCES, INC.owner
- Houghton Michaeldirector
- Schornstein Alexanderowner
- White Nicole SChief Manufacturing Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.